Malaria medicines to address drug resistance and support malaria elimination efforts

References

• WHO., World malaria report. 2016. Available from: http://www.who.int/malaria/publications/world-malaria-report-2016/report/en/
   Google Scholar
• O’Meara WP, Mangeni JN, Steketee R, et al. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis. 2010;10(8):545–555.
   PubMed Web of Science ®Google Scholar
• Greenwood D. The quinine connection. J Antimicrob Chemother. 1992;30(4):417–427.
   PubMed Web of Science ®Google Scholar
• Kaufman TS, Ruveda EA. The quest for quinine: those who won the battles and those who won the war. Angew Chem Int Ed Engl. 2005;44(6):854–885.
   PubMed Web of Science ®Google Scholar
• Packard RM. The origins of antimalarial-drug resistance. N Engl J Med. 2014;371(5):397–399.
   PubMed Web of Science ®Google Scholar
• Butler AR, Khan S, Ferguson E. A brief history of malaria chemotherapy. J R Coll Physicians Edinb. 2010;40(2):172–177.
   PubMedGoogle Scholar
• Guttmann P, Ehrlich P. Über die wirkung des methylenblau bei malaria [On the effect of methylene blue on malaria]. Berliner Klinische Wochenschrift. 1891;28:953–956.
   Google Scholar
• Schlitzer M. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem Med Chem. 2007;2(7):944–986.
   Web of Science ®Google Scholar
• Peters W. Antimalarial drugs and their actions. Postgrad Med J. 1973;49(574):573–583.
   PubMed Web of Science ®Google Scholar
• Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg. 1963;12:121–128.
   PubMed Web of Science ®Google Scholar
• Greenwood D. Conflicts of interest: the genesis of synthetic antimalarial agents in peace and war. J Antimicrob Chemother. 1995;36(5):857–872.
   PubMed Web of Science ®Google Scholar
• Meshnick SR, Dobson MJ The history of antimalarial drugs. In: Rosenthal PJ, editor. Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. Totowa: Humana; 2001. p. 15–25.
   Google Scholar
• Shanks GD. 1993 Sir Henry Wellcome Medal and Prize recipient. The rise and fall of mefloquine as an antimalarial drug in South East Asia. Mil Med. 1994;159(4):275–281.
   PubMed Web of Science ®Google Scholar
• Castel DA. Antimalarial agents. In: Abraham DJ, editor. Burger’s medicinal chemistry and drug discovery. New York: Wiley; 2003. p. 943.
   Google Scholar
• Colwell WT, Brown V, Christie P, et al. Antimalarial arylaminopropanols. J Med Chem. 1972;15(7):771–775.
   PubMed Web of Science ®Google Scholar
• Faurant C. From bark to weed: the history of artemisinin. Parasite. 2011;18(3):215–218.
   PubMed Web of Science ®Google Scholar
• Miller LH, Su X. Artemisinin: discovery from the Chinese herbal garden. Cell. 2011;146(6):855–858.
   PubMed Web of Science ®Google Scholar
• Haynes RK, Vonwiller SC From Qinghao, marvelous herb of antiquity, to the antimalarial trioxane Qinghaosu and some remarkable new chemistry. Acc Chem Res. 1997;30(2):73–79.
   Web of Science ®Google Scholar
• White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320(5874):330–334.
   PubMed Web of Science ®Google Scholar
• White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today. 1996;12(10):399–401.
   PubMedGoogle Scholar
• White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113(8):1084–1092.
   PubMed Web of Science ®Google Scholar
• White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997;41(7):1413–1422.
   PubMed Web of Science ®Google Scholar
• WHO, Guidelines for the treatment of malaria. 2015. Available from: http://www.who.int/malaria/publications/atoz/9789241549127/en/
   Google Scholar
• Enserink M. Combating malaria. Malaria treatment: ACT two. Science. 2007;318(5850):560–563.
   PubMed Web of Science ®Google Scholar
• Owens S. Malaria and the millennium development goals. Arch Dis Child. 2015;100(Suppl 1):S53–6.
   PubMedGoogle Scholar
• WHO. Overview of malaria treatment. 2017. Available from: http://www.who.int/malaria/areas/treatment/overview/en/
   Google Scholar
• WHO. The global plan for artemisinin resistance containment. 2011. Available from: http://www.who.int/malaria/publications/atoz/artemisinin_resistance_containment_2011.pdf
   Google Scholar
• Zofou D. A diversity of approaches to address the challenge of drug-resistance in malaria. J Biotechnol Biomaterial. 2011;1(7):1–3.
   Google Scholar
• Abdi YA, Gustafsson LL, Ericsson O, et al. Handbook of drugs for tropical parasitic infections. 2nd ed. London: Taylor & Francis; 1995.
   Google Scholar
• Wernsdorfer WH, Payne D. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther. 1991;50(1):95–121.
   PubMed Web of Science ®Google Scholar
• Young MD, Moore DV. Chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg. 1961;10:317–320.
   PubMed Web of Science ®Google Scholar
• Moore DV, Lanier JE. Observations on two Plasmodium falciparum infections with an abnormal response to chloroquine. Am J Trop Med Hyg. 1961;10:5–9.
   PubMed Web of Science ®Google Scholar
• Maberti S. Desarrollo de resistencia a la pyrimetamine, apresentación de 15 casos estudiados en Trujillo. Venezuela Arch Venez Med Trop Parasitol Med. 1960;3:239–259.
   PubMedGoogle Scholar
• Peters. W. Resistance of human malaria I, III and IV. Chemotherapy and drug resistance in malaria. London: Academic Press; 1987. p. 543–68, 593–658, 659 & 786.
   Google Scholar
• Wongsrichanalai C, Pickard AL, Wernsdorfer WH, et al. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2(4):209–218.
   PubMed Web of Science ®Google Scholar
• Wootton JC, Feng X, Ferdig MT, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature. 2002;418(6895):320–323.
   PubMed Web of Science ®Google Scholar
• Roper C, Pearce R, Nair S, et al. Intercontinental spread of pyrimethamine-resistant malaria. Science. 2004;305(5687):1124.
   PubMed Web of Science ®Google Scholar
• Bjorkman A, Phillips-Howard PA. The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg. 1990;84(2):177–180.
   PubMed Web of Science ®Google Scholar
• WHO. The use of antimalarial drugs. Report of an informal consultation. 2001. Geneva. Available from: http://apps.who.int/iris/bitstream/10665/66961/1/WHO_CDS_RBM_2001.33.pdf
   Google Scholar
• Aramburú Guarda J, Asayag CR, Witzig R. Malaria reemergence in the Peruvian Amazon region. Emerg Infect Dis. 5(2):209–215.
   PubMed Web of Science ®Google Scholar
• Vasconcelos KF, Plowe CV, Fontes CJ, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Mem Inst Oswaldo Cruz. 2000;95(5):721–728.
   PubMed Web of Science ®Google Scholar
• Ronn AM, Msangeni HA, Mhina J, et al. High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg. 1996;90(2):179–181.
   PubMed Web of Science ®Google Scholar
• Choudhury DS, Sinha S, Ghosh SK, et al. Report of a case of P. falciparum malaria resistant to chloroquine and combination of sulfalene and pyrimethamine in Delhi. Indian J Malariol. 1987;24(1):95–96.
   PubMedGoogle Scholar
• Zalis MG, Pang L, Silveira MS, et al. Characterization of Plasmodium falciparum isolated from the Amazon region of Brazil: evidence for quinine resistance. Am J Trop Med Hyg. 1998;58(5):630–637.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Grobusch MP, Loscher T. Patterns of Plasmodium falciparum drug resistance in nonimmune travellers to Africa. Eur J Clin Microbiol Infect Dis. 2001;20(4):284–286.
   PubMed Web of Science ®Google Scholar
• Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, et al. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. Southeast Asian J Trop Med Public Health. 2001;32(1):41–49.
   PubMedGoogle Scholar
• Mockenhaupt FP. Mefloquine resistance in Plasmodium falciparum. Parasitol Today. 1995;11(7):248–253.
   PubMedGoogle Scholar
• Hall AP, Segal HE, Pearlman EJ, et al. Amodiaquine resistant falciparum malaria in Thailand. Am J Trop Med Hyg. 1975;24(4):575–580.
   PubMed Web of Science ®Google Scholar
• Eastman RT, Dharia NV, Winzeler EA, et al. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother. 2011;55(8):3908–3916.
   PubMed Web of Science ®Google Scholar
• Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359(24):2619–2620.
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455–467.
   PubMed Web of Science ®Google Scholar
• White NJ. Preventing antimalarial drug resistance through combinations. Drug Resist Updat. 1998;1(1):3–9.
   PubMed Web of Science ®Google Scholar
• White NJ, Hien TT, Nosten FH. A brief history of Qinghaosu. Trends Parasitol. 2015;31(12):607–610.
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for the treatment of malaria. Geneva, Switzerland: World Health Organisation (WHO); 2006.
   Google Scholar
• Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50–55.
   PubMed Web of Science ®Google Scholar
• Takala-Harrison S, Laufer MK. Antimalarial drug resistance in Africa: key lessons for the future. Ann NY Acad Sci. 2015;1342:62–67.
   PubMed Web of Science ®Google Scholar
• Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15(4):415–421.
   PubMed Web of Science ®Google Scholar
• Vreden SG, Jitan JK, Bansie RD, et al. Evidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemether. Mem Inst Oswaldo Cruz. 2013;108(8):968–973.
   PubMed Web of Science ®Google Scholar
• Chenet SM, Akinyi Okoth S, Huber CS, et al. Independent emergence of the Plasmodium falciparum Kelch propeller domain mutant allele C580Y in Guyana. J Infect Dis. 2016;213(9):1472–1475.
   PubMed Web of Science ®Google Scholar
• Rahman R, Martin MJS, Persaud S, et al. Continued sensitivity of Plasmodium falciparum to artemisinin in Guyana, with absence of Kelch propeller domain mutant alleles. Open Forum Infect Dis. 2016;3(3):ofw185.
   PubMed Web of Science ®Google Scholar
• WHO., Global Malaria Programme Status report. Artemisinin and artemisinin-based combination therapy resistance. 2016. Available from: http://apps.who.int/iris/bitstream/10665/250294/1/WHO-HTM-GMP-2016.11-eng.pdf
   Google Scholar
• Lu F, Culleton R, Zhang M, et al. Emergence of Indigenous artemisinin-resistant plasmodium falciparum in Africa. N Engl J Med. 2017;376(10):991–993.
   PubMed Web of Science ®Google Scholar
• Regional Office for Africa, W.H.O. Framework for developing, implementing, and updating antimalaria treatment policy: a guide for country malaria control programmes. Brazzaville: World Health Organisation, Regional Office for Africa; 2003.
   Google Scholar
• Bloland PB, Lackritz EM, Kazembe PN, et al. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis. 1993;167(4):932–937.
   PubMed Web of Science ®Google Scholar
• Nwanyanwu OC, Ziba C, Kazembe P, et al. Efficacy of sulphadoxine/pyrimethamine for Plasmodium falciparum malaria in Malawian children under five years of age. Trop Med Int Health. 1996;1(2):231–235.
   PubMed Web of Science ®Google Scholar
• Attaran A, Barnes KI, Curtis C, et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet. 2004;363(9404):237–240.
   PubMed Web of Science ®Google Scholar
• Regional Office for the Western Pacific, W.H.O. Emergency response to artemisinin resistance in the Greater Mekong sub region: regional framework for action 2013-2015. Manila, Philippines: World Health Organisation (WHO), Regional Office for the Western Pacific; 2013.
   Google Scholar
• Bustos MD, Wongsrichanalai C, Delacollette C, et al. Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010. Southeast Asian J Trop Med Public Health. 2013;44(Suppl 1):201–30; discussion 306–7.
   PubMedGoogle Scholar
• Wongsrichanalai C. Artemisinin resistance or artemisinin-based combination therapy resistance? Lancet Infect Dis. 2013;13(2):114–115.
   PubMed Web of Science ®Google Scholar
• Looareesuwan S, Wilairatana P, Chalermarut K, et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 1999;60(4):526–532.
   PubMed Web of Science ®Google Scholar
• Korsinczky M, Chen N, Kotecka B, et al. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother. 2000;44(8):2100–2108.
   PubMed Web of Science ®Google Scholar
• Sagara I, Beavogui AH, Zongo I, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016;16(2):189–198.
   PubMed Web of Science ®Google Scholar
• Ramharter M, Kurth F, Schreier AC, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis. 2008;198(6):911–919.
   PubMed Web of Science ®Google Scholar
• Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010;375(9724):1457–1467.
   PubMed Web of Science ®Google Scholar
• Kayentao K, Doumbo OK, Penali LK, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J. 2012;11:364.
   PubMed Web of Science ®Google Scholar
• Duparc S, Borghini-Fuhrer I, Craft CJ, et al. Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J. 2013;12:70.
   PubMed Web of Science ®Google Scholar
• Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med. 2012;366(14):1298–1309.
   PubMed Web of Science ®Google Scholar
• Leang R, Canavati SE, Khim N, et al. Efficacy and safety of pyronaridine-artesunate for treatment of uncomplicated Plasmodium falciparum malaria in Western Cambodia. Antimicrob Agents Chemother. 2016;60(7):3884–3890.
   PubMed Web of Science ®Google Scholar
• Boni MF, White NJ, Baird JK. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLoS Med. 2016;13(3):e1001984.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Triple therapy regimens: a study by the tracking resistance to artemisinin collaboration (TRACII). NCT02453308. 2015.
   Google Scholar
• WWARN. Tracking resistance to artemisinin collaboration II. [cited 2017 May 1]. Available from: http://www.wwarn.org/working-together/partner-projects/tracking-resistance-artemisinin-collaboration-ii.
   Google Scholar
• Nguyen TD, Olliaro P, Dondorp AM, et al. Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob Health. 2015;3(12):e758–66.
   PubMed Web of Science ®Google Scholar
• Boni MF, Smith DL, Laxminarayan R. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA. 2008;105(37):14216–14221.
   PubMed Web of Science ®Google Scholar
• Smith DL, Klein EY, McKenzie FE, et al. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J. 2010;9:217.
   PubMed Web of Science ®Google Scholar
• Antao T, Hastings I. Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach. Malar J. 2012;11:422.
   PubMed Web of Science ®Google Scholar
• WHO. Eliminating malaria in the Greater Mekong subregion. 2016. Available from: http://www.who.int/malaria/publications/atoz/eliminating-malaria-greater-mekong/en/.
   Google Scholar
• WHO. Evidence review group on mass drug administration, mass screening and treatment and focal screening and treatment. 2015. Available from: http://www.who.int/malaria/mpac/mpac-sept2015-erg-mda-report.pdf
   Google Scholar
• Wongsrichanalai C, Sibley CH. Fighting drug-resistant Plasmodium falciparum: the challenge of artemisinin resistance. Clin Microbiol Infect. 2013;19(10):908–916.
   PubMed Web of Science ®Google Scholar
• Hanboonkunupakarn B, Ashley EA, Jittamala P, et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult Thai subjects. Antimicrob Agents Chemother. 2014;58(12):7340–7346.
   PubMed Web of Science ®Google Scholar
• Jittamala P, Pukrittayakamee S, Ashley EA, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2015;59(1):505–513.
   PubMed Web of Science ®Google Scholar
• Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.
   PubMed Web of Science ®Google Scholar
• Steketee RW, Ter Kuile F. Single low-dose primaquine to reduce malaria transmission. Lancet Infect Dis. 2014;14(2):91–92.
   PubMed Web of Science ®Google Scholar
• Eziefula AC, Bousema T, Yeung S, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis. 2014;14(2):130–139.
   PubMed Web of Science ®Google Scholar
• WHO. Updated WHO policy recommendation: single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. 2012. http://www.who.int/malaria/publications/atoz/who_pq_policy_recommendation/en/.
   Google Scholar
• Dicko A, Brown JM, Diawara H, et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. Lancet Infect Dis. 2016;16(6):674–684.
   PubMed Web of Science ®Google Scholar
• Goncalves BP, Tiono AB, Ouédraogo A, et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. BMC Med. 2016;14:40.
   PubMed Web of Science ®Google Scholar
• Okebe J, Bousema T, Affara M, et al. The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin-piperaquine in asymptomatic parasite carriers in the Gambia: a randomized controlled trial. EBioMedicine. 2016;13:348–355.
   PubMed Web of Science ®Google Scholar
• Chen I, Poirot E, Newman M, et al. An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa. Malar J. 2015;14:204.
   PubMed Web of Science ®Google Scholar
• Flannery EL, Chatterjee AK, Winzeler EA. Antimalarial drug discovery - approaches and progress towards new medicines. Nat Rev Microbiol. 2013;11(12):849–862.
   PubMed Web of Science ®Google Scholar
• Alonso PL, Brown G, Arevalo-Herrera M, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011;8(1):e1000406.
   PubMed Web of Science ®Google Scholar
• Burrows JN, Hooft Van Huijsduijnen R, Mohrle JJ, et al. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187.
   PubMed Web of Science ®Google Scholar
• Diagana TT. Supporting malaria elimination with 21st century antimalarial agent drug discovery. Drug Discov Today. 2015;20(10):1265–1270.
   PubMed Web of Science ®Google Scholar
• Wells TN, van Huijsduijnen RH, van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015;14(6):424–442.
   PubMed Web of Science ®Google Scholar
• Pandey AV, Tekwani BL, Singh RL, et al. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem. 1999;274(27):19383–19388.
   PubMed Web of Science ®Google Scholar
• Kreidenweiss A, Mordmüller B, Krishna S, et al. Antimalarial activity of a synthetic endoperoxide (RBx-11160/OZ277) against Plasmodium falciparum isolates from Gabon. Antimicrob Agents Chemother. 2006;50(4):1535–1537.
   PubMed Web of Science ®Google Scholar
• Vennerstrom JL, Arbe-Barnes S, Brun R, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature. 2004;430(7002):900–904.
   PubMed Web of Science ®Google Scholar
• Valecha N, Krudsood S, Tangpukdee N, et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin Infect Dis. 2012;55(5):663–671.
   PubMed Web of Science ®Google Scholar
• Aditya S. Arterolane maleate and piperaquine phosphate: a new option in the treatment of Plasmodium falciparum malaria. J Drug Discov Ther. 2013;1(3):66–69.
   Google Scholar
• Central Drugs Standard Control Organization, C., List of drug approved for marketing in India. 2011. Available from: http://www.cdsco.nic.in/forms/list.aspx?lid=2034&Id=11.
   Google Scholar
• ClinicalTrials.gov. Arterolane-PQP Versus DHA-PQP in uncomplicated falciparum malaria in Eastern Myanmar. ClinicalTrials.gov Identifier: NCT024611862015. ClinicalTrials.gov, USA, 2015.
   Google Scholar
• Charman SA, Arbe-Barnes S, Bathurst IC, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA. 2011;108(11):4400–4405.
   PubMed Web of Science ®Google Scholar
• Phyo AP, Jittamala P, Nosten FH, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis. 2016;16(1):61–69.
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Baker M, O’Rourke P, et al. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers. J Antimicrob Chemother. 2016;71(9):2620–2627.
   PubMed Web of Science ®Google Scholar
• White NJ, Pukrittayakamee S, Phyo AP, et al. Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med. 2014;371(5):403–410.
   PubMed Web of Science ®Google Scholar
• Wu T, Nagle A, Kuhen K, et al. Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J Med Chem. 2011;54(14):5116–5130.
   PubMed Web of Science ®Google Scholar
• Nagle A, Wu T, Kuhen K, et al. Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. J Med Chem. 2012;55(9):4244–4273.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Efficacy, safety, tolerability and pharmacokinetics of KAF156 in adult patients with acute, uncomplicated Plasmodium falciparum or vivax malaria mono-infection. NCT01753323. 2014.
   Google Scholar
• McNamara CW, Lee MC, Lim CS, et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature. 2013;504(7479):248–253.
   PubMed Web of Science ®Google Scholar
• Alexandra. F. Malaria: a step closer to elimination? Nat Rev Drug Discov. 2014;13:20.
   PubMed Web of Science ®Google Scholar
• WHO. Responding to antimalarial drug resistance. 2017. Available from: http://www.who.int/malaria/areas/drug_resistance/overview/en/
   Google Scholar
• Pribluda VS, Evans L, Barillas E, et al. Were medicine quality and pharmaceutical management contributing factors in diminishing artemisinin efficacy in Guyana and Suriname? Malar J. 2014;13:77.
   PubMed Web of Science ®Google Scholar
• Chrubasik C, Jacobson RL. The development of artemisinin resistance in malaria: reasons and solutions. Phytother Res. 2010;24(7):1104–1106.
   PubMed Web of Science ®Google Scholar